Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates

Journal of Clinical Microbiology

Volumn 48, Issue 8, 2010, Pages 2749-2753

  Van Ingen, Jakko ^a,b   Simons, Sami ^b   De Zwaan, Rina ^a   Van Der Laan, Tridia ^a   Kamst van Agterveld, Miranda ^a   Boeree, Martin J ^b   Van Soolingen, Dick ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CAPREOMYCIN; CLOFAZIMINE; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; BACTERIAL DNA; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS; GENOTYPE; GOLD STANDARD; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MTBDRSL ASSAY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM GROWTH INDICATOR TUBE AUTOMATED LIQUID CULTURE SYSTEM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RELIABILITY; DRUG EFFECTS; EVALUATION STUDY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; NETHERLANDS; PROCEDURES;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS COMPLEX;

AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; PHENOTYPE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77955441365     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00652-10     Document Type: Article

References (19)

1. David, H. L., N. Rastogi, S. Clavel-Sérès, and F. Clément. 1987. Studies on clofazimine-resistance in mycobacteria: is the inability to isolate drug-resistance mutants related to its mode of action? Zentralbl. Bakteriol. Mikrobiol. Hyg. A 266:292-304.
2. Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442.
3. Global Alliance for TB Drug Development. 2008. Handbook of anti-tuberculosis agents. Tuberculosis 88:85-170.
4. Hain Lifescience. 2009. GenoType MTBDRsl manual v1.0. Hain Lifescience, Nehren, Germany. http://www.hain-lifescience.de/en/downloads/microbiology.html.
5. Hillemann, D., S. Rusch-Gerdes, and E. Richter. 2009. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47:1767-1772.
6. Hofmann-Thiel, S., J. van Ingen, K. Feldmann, L. Turaev, G. T. Uzakova, G. Murmusaeva, D. van Soolingen, and H. Hoffmann. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur. Respir. J. 33:368-374.
7. Krüüner, A., M. D. Yates, and F. A. Drobniewsi. 2006. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:811-818.
8. Maus, C. E., B. B. Plikaytis, and T. M. Shinnick. 2005. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:3192-3197.
9. Nijland, H. J., R. Ruslami, A. Juwono Suroto, D. M. Burger, B. Alisjahbana, R. van Crevel, and R. E. Aarnoutse. 2007. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis. 45:1001-1007.
10. Nuermberger, E., and J. Grosset. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:243-255.
11. Piersimoni, C., C. Lacchini, V. Penati, E. Iona, L. Fattorini, D. Nista, D. Zallocco, G. P. Gesu, and L. Codecasa. 2007. Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin. Diagn. Microbiol. Infect. Dis. 57:283-287.
12. Rodrigues, C., J. Jani, S. Shenai, P. Thakkar, S. Siddiqi, and A. Mehta. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the BACTEC MGIT 960 system. Int. J. Tuberc. Lung Dis. 12:1449-1455.
13. Rüsch-Gerdes, S., G. E. Pfyffer, M. Casal, M. Chadwick, and S. Siddiqi. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol. 44:688-692.
14. Rustomjee, R., C. Lienhardt, T. Kanyok, G. R. Davies, J. Levin, T. Mthiyane, C. Reddy, A. W. Sturm, F. A. Sirgel, J. Allen, D. J. Coleman, B. Fourie, D. A. Mitchison, et al. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138.
15. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
16. Springer, B., K. Lucke, R. Calligaris-Maibach, C. Ritter, and E. C. Böttger. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J. Clin. Microbiol. 47:1773-1780.
17. Tortoli, E., D. Dionisio, and C. Fabbri. 2004. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J. Chemother. 16:334-336.
18. van Ingen, J., M. J. Boeree, A. Wright, T. van der Laan, P. N. R. Dekhuijzen, and D. van Soolingen. 2008. Second-line drug resistance in multi-drug resistant tuberculosis cases of various origins in the Netherlands. Int. J. Tuberc. Lung Dis. 12:1295-1299.
19. van Ingen, J., T. van der Laan, P. N. R. Dekhuijzen, M. J. Boeree, and D. van Soolingen. 2010. In vitro drug susceptibility of 2275 clinical nontuberculous Mycobacterium isolates of 49 species in the Netherlands. Int. J. Antimicrob. Agents 35:169-173.